{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:04:08Z","timestamp":1779685448328,"version":"3.53.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Differentiated high-grade thyroid carcinoma (DHGTC) is relatively uncommon. This case report described a 61-year-old male initially diagnosed with classic papillary thyroid carcinoma confined to the thyroid gland, accompanied by skip metastasis to a Level II lymph node. The metastatic lymph node exhibited histopathological progression to DHGTC. Following thyroidectomy for the primary tumor and neck dissection for the metastatic lymph node, the patient received adjuvant radiotherapy to the neck. Subsequently, pathological examination confirmed multiple pulmonary metastases (PMs) from DHGTC within six months of the initial diagnosis. Unfortunately, a post-therapeutic \u00b9\u00b3\u00b9I scan revealed no uptake in the PMs. Genetic testing of the PMs revealed no mutations in BRAF, KRAS, or NRAS, and no RET rearrangement. The patient\u2019s condition was subsequently managed with targeted therapy and immunotherapy, which achieved disease stabilization.<\/jats:p>","DOI":"10.3389\/fonc.2026.1790374","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:46:50Z","timestamp":1779684410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Tuya","family":"E","sequence":"first","affiliation":[{"name":"Department of Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieraili","family":"Wumener","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"B2","volume-title":"Endocrine and neuroendocrine tumours","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0350","article-title":"Prevalence of differentiated high-grade thyroid carcinoma among well-differentiated tumors: a systematic review and meta-analysis","volume":"34","author":"Poma","year":"2024","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125535","article-title":"Aggressive thyroid carcinomas clinical and molecular features: a systematic review","volume":"26","author":"Schipor","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/his.14550","article-title":"Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases","volume":"80","author":"Xu","year":"2022","journal-title":"Histopathology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02441-y","article-title":"2020 Chinese guidelines for ultrasound maligancy risk stratification of thyroid nodules: the C-TIRADS","volume":"70","author":"Zhou","year":"2020","journal-title":"Endocrine"},{"key":"B7","volume-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"B8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07222-1","article-title":"Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)","volume":"52","author":"Lin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0033","article-title":"NCCN guidelines\u00ae insights: thyroid carcinoma, version 1.2025","volume":"23","author":"Haddad","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S200628","article-title":"Prevalence, risk factors and location of skip metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis","volume":"11","author":"Qiu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.743900","article-title":"A specific predicting model for screening skip metastasis from patients with negative central lymph nodes metastasis in papillary thyroid cancer","volume":"12","author":"Yang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.793997","article-title":"Features of lymph node metastasis and structural recurrence in papillary thyroid carcinoma located in the upper portion of the thyroid: a retrospective cohort study","volume":"12","author":"Heng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0499","article-title":"High-grade follicular cell-derived non-anaplastic thyroid carcinoma: correlating extent of invasion and mutation profile with oncologic outcome","volume":"35","author":"Scholfield","year":"2025","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09778-w","article-title":"Incidence and clinicopathological features of differentiated high-grade thyroid carcinomas: an institutional experience","volume":"34","author":"Jeong","year":"2023","journal-title":"Endocr Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002371","article-title":"High-grade papillary thyroid carcinoma, diffuse sclerosing subtype: a series of 18 cases detailing the pathologic features, potential for misdiagnosis, and aggressive clinical behavior","volume":"49","author":"Ghossein","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf050","article-title":"Decoding lymph node skip metastasis: impact on long-term outcomes in stage T1 papillary thyroid carcinoma","volume":"192","author":"Cai","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1507\/endocrj.EJ14-0293","article-title":"Prognostic classification of thyroid follicular cell tumors using Ki-67 labeling index: risk stratification of thyroid follicular cell carcinomas","volume":"62","author":"Kakudo","year":"2015","journal-title":"Endocr J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09770-4","article-title":"High grade differentiated follicular cell-derived thyroid carcinoma versus poorly differentiated thyroid carcinoma: a clinicopathologic analysis of 41 cases","volume":"34","author":"Thompson","year":"2023","journal-title":"Endocr Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31060252","article-title":"A comprehensive review and insights into the new entity of differentiated high-grade thyroid carcinoma","volume":"31","author":"Harahap","year":"2024","journal-title":"Curr Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4158\/EP161431.OR","article-title":"Death related to pulmonary metastasis in patients with differentiated thyroid cancer","volume":"23","author":"Leite","year":"2017","journal-title":"Endocr Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-018-0786-0","article-title":"Novel targeted therapies and immunotherapy for advanced thyroid cancers","volume":"17","author":"Naoum","year":"2018","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3417","article-title":"Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers","volume":"30","author":"French","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/s41467-025-68108-2","article-title":"Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial","volume":"17","author":"Chen","year":"2026","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00376-6","article-title":"Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study","volume":"26","author":"Shi","year":"2025","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1544604","article-title":"A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report","volume":"16","author":"Chai","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1477954","article-title":"Efficacy of combined immunotherapy and targeted therapy in overcoming barriers to postoperative recurrence in squamous subtype anaplastic thyroid carcinoma with abscess: a case report and literature review","volume":"15","author":"Jiang","year":"2025","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1790374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:46:59Z","timestamp":1779684419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1790374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1790374"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1790374","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1790374"}}